Open AccessRandomized trial of thrombolysis versus heparin in unstable angina.
Author(s) -
Theodore Schreiber,
David G. Rizik,
Christopher J. White,
G.V.R.K. Sharma,
Michael J. Cowley,
Gregory Macina,
Priya Reddy,
Louis Kantounis,
GERALD C. TIMMIS,
Ann Margulis
Publication year - 1992
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.86.5.1407
Subject(s) - medicine , urokinase , unstable angina , thrombolysis , myocardial infarction , streptokinase , angina , randomized controlled trial , aspirin , clinical endpoint , placebo , heparin , cardiology , revascularization , anesthesia , alternative medicine , pathology
The clinical usefulness of intravenous thrombolytic therapy in unstable angina is currently unknown, despite the pathogenetic similarity of this entity to acute myocardial infarction, for which thrombolysis has enjoyed great success. To compare the clinical benefit of intravenous urokinase with that of conventional antithrombotic therapy in preventing the progression of unstable angina to new myocardial infarction, intractable angina, or death within the first 96 hours after hospitalization, 149 patients with unstable angina were randomized to one of two intravenous thrombolytic strategies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom